Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age
1상
완료
NCT04520659
| 대상 질환 | RSV Infection |
|---|
| 임상 단계 | 1상 |
|---|
| 스폰서 | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 81 명 |
|---|
| 중재(약물) | RSV LID/ΔM2-2/1030s |
|---|
| 시작일 | 2022년 3월 16일 |
|---|
| 완료일 | 2024년 4월 18일 |
|---|
| 결과 공개일 | 2025년 8월 22일 |
|---|
요약
The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of a single dose of a recombinant, live-attenuated respiratory syncytial virus (RSV) vaccine, LID/ΔM2-2/1030s, in RSV-seronegative infants and children 6 to 24 months of age.
Frequency of Grade 1 or Higher Solicited Adverse Events (AEs) by Grade
Measured through Day 28 · Participants
| Group 1: RSV LID/ΔM2-2/1030s | 14 Participants |
|---|
| Group 1: Placebo | 7 Participants |
|---|
| Group 2: RSV LID/ΔM2-2/1030s | 27 Participants |
|---|
| Group 2: Placebo | 11 Participants |
|---|
| Groups 1 and 2 Combined: RSV LID/ΔM2-2/1030s | 41 Participants |
|---|
| Groups 1 and 2 Combined: Placebo | 18 Participants |
|---|
Frequency of Grade 2 or Higher Lower Respiratory Infections (LRI) by Grade
Measured through Day 28 · Participants
| Group 1: RSV LID/ΔM2-2/1030s | 14 Participants |
|---|
| Group 1: Placebo | 7 Participants |
|---|
| Group 2: RSV LID/ΔM2-2/1030s | 39 Participants |
|---|
| Group 2: Placebo | 17 Participants |
|---|
| Groups 1 and 2 Combined: RSV LID/ΔM2-2/1030s | 53 Participants |
|---|
| Groups 1 and 2 Combined: Placebo | 24 Participants |
|---|
Number of Participants With Unsolicited Adverse Events (AEs) by Grade of Severity
Measured through Day 28 · Participants
| Group 1: RSV LID/ΔM2-2/1030s | 14 Participants |
|---|
| Group 1: Placebo | 6 Participants |
|---|
| Group 2: RSV LID/ΔM2-2/1030s | 29 Participants |
|---|
| Group 2: Placebo | 16 Participants |
|---|
| Groups 1 and 2 Combined: RSV LID/ΔM2-2/1030s | 43 Participants |
|---|
| Groups 1 and 2 Combined: Placebo | 22 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.